Active Ingredient(s):Cabotegravir + Rilpivirine FDA Approved: * January 21, 2021 Pharm Company: *VIIV HLTHCARE Category:HIV / AIDS
Cabotegravir/rilpivirine, sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS. It contains cabotegravir and rilpivirine in a package with two separate injection vials.
The most common adverse reactions include injection site reactions, fever or feeling hot (pyrexia), fatigue, headache, musculoskeletal pain...
* May have multiple approval dates, manufacturers, or labelers.